Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 240

1.

Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors.

Cadarette SM, Solomon DH, Katz JN, Patrick AR, Brookhart MA.

Osteoporos Int. 2011 Mar;22(3):943-54. doi: 10.1007/s00198-010-1309-z. Epub 2010 Jun 8.

2.

Comparative effectiveness of osteoporosis drugs in preventing secondary nonvertebral fractures in Taiwanese women.

Lin TC, Yang CY, Yang YH, Lin SJ.

J Clin Endocrinol Metab. 2013 Dec;98(12):4717-26. doi: 10.1210/jc.2013-1877. Epub 2013 Sep 30.

PMID:
24081731
3.

Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.

Cadarette SM, Katz JN, Brookhart MA, Stürmer T, Stedman MR, Solomon DH.

Ann Intern Med. 2008 May 6;148(9):637-46.

4.
5.

Does medication adherence itself confer fracture protection? An investigation of the healthy adherer effect in observational data.

Curtis JR, Yun H, Lange JL, Matthews R, Sharma P, Saag KG, Delzell E.

Arthritis Care Res (Hoboken). 2012 Dec;64(12):1855-63. doi: 10.1002/acr.21759.

6.

Medical treatment of vertebral osteoporosis.

Lippuner K.

Eur Spine J. 2003 Oct;12 Suppl 2:S132-41. Epub 2003 Sep 17. Review.

7.

Health-economic comparison of three recommended drugs for the treatment of osteoporosis.

Brecht JG, Kruse HP, Möhrke W, Oestreich A, Huppertz E.

Int J Clin Pharmacol Res. 2004;24(1):1-10.

PMID:
15575171
8.
9.

Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries.

Wang Z, Ward MM, Chan L, Bhattacharyya T.

Osteoporos Int. 2014 Aug;25(8):2109-16. doi: 10.1007/s00198-014-2738-x. Epub 2014 May 21.

10.

Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women.

Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C, Deswaef A, Verpooten GA, Reginster JY.

Osteoporos Int. 2008 Jun;19(6):811-8.

PMID:
17999022
11.

Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.

Abelson A, Ringe JD, Gold DT, Lange JL, Thomas T.

Osteoporos Int. 2010 Jun;21(6):1021-9. doi: 10.1007/s00198-009-1046-3. Epub 2009 Sep 1.

12.

Incidence and risk of venous thromboembolism among Taiwan osteoporotic fracture population under osteoporosis pharmacological treatments.

Lin TC, Lee CH, Yang CY, Yang YH, Lin SJ.

J Clin Endocrinol Metab. 2014 May;99(5):1599-607. doi: 10.1210/jc.2013-3114. Epub 2014 Feb 25.

PMID:
24606074
13.

Fractures in women treated with raloxifene or alendronate: a retrospective database analysis.

Foster SA, Shi N, Curkendall S, Stock J, Chu BC, Burge R, Diakun DR, Krege JH.

BMC Womens Health. 2013 Mar 23;13:15. doi: 10.1186/1472-6874-13-15.

14.

Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort.

Kim SY, Schneeweiss S, Katz JN, Levin R, Solomon DH.

J Bone Miner Res. 2011 May;26(5):993-1001. doi: 10.1002/jbmr.288.

15.

Hip fractures in users of first- vs. second-generation bisphosphonates.

Mamdani M, Kopp A, Hawker G.

Osteoporos Int. 2007 Dec;18(12):1595-600. Epub 2007 Sep 1.

PMID:
17767369
16.

Fractures and mortality in relation to different osteoporosis treatments.

Yun H, Delzell E, Saag KG, Kilgore ML, Morrisey MA, Muntner P, Matthews R, Guo L, Wright N, Smith W, Colón-Emeric C, O'Connor CM, Lyles KW, Curtis JR.

Clin Exp Rheumatol. 2015 May-Jun;33(3):302-9. Epub 2014 Jul 28.

PMID:
25068266
17.

GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates.

Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T.

Osteoporos Int. 2012 Jan;23(1):223-31. doi: 10.1007/s00198-011-1535-z. Epub 2011 Feb 10.

PMID:
21308365
18.
19.

Bisphosphonate use and subsequent hip fracture in South Korea.

Lee YK, Ha YC, Choi HJ, Jang S, Park C, Lim YT, Shin CS.

Osteoporos Int. 2013 Nov;24(11):2887-92. doi: 10.1007/s00198-013-2395-5. Epub 2013 May 17.

PMID:
23681088
20.

Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women.

Ellis AG, Reginster JY, Luo X, Bushmakin AG, Williams R, Sutradhar S, Mirkin S, Jansen JP.

Curr Med Res Opin. 2014 Aug;30(8):1617-26. doi: 10.1185/03007995.2014.908279. Epub 2014 May 2. Review.

PMID:
24773456
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk